Clinical Updates on Substance-P Antagonist in Pain Management

Haroon Khan

Department of Pharmacy, Abdul Wali Khan University Mardan 23200, Pakistan

Corresponding author: Haroon Khan Ph.D., M. Phil., B. Pharm, Associate Professor and Chairman Department of Pharmacy, Abdul Wali Khan University Mardan 23200, Pakistan, Tel: +92-3329123171; Email: hkd2006@gmail.com

Received date: October 14, 2014 Accepted date: October 16, 2014 Published date: October 23, 2014

Copyright: © 2014 Khan H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Novel drug designing and development is the need and the decisive target of pharmaceutical industry, as the active life of a drug is not very extensive. Substance P (SP) is considered as the prototypic neuropeptide of the more than 50 known neuroactive molecules, and is also the member of a new neurotransmitter system that belongs to the family of three related peptides known as neurokinins and a member of the seven-transmembrane G-protein coupled family of receptors and is primarily associated with sensory neurons in the periphery and specific areas of the CNS [1,2]. The other two members are simply called neurokinin A and neurokinin B. Modulation of SP activity offered a radical new approach to the management of depression, anxiety, stress and is involved in several physiologic cardio-vascular tone, stimulation of salivary secretion, smooth muscle periphery and specific areas of the CNS [1,2]. The other two members of the family of three related peptides known as neurokinins and a but also in other areas such as the nucleus accumbens which mediate the motivational properties of both natural rewards and drugs [5].

Substance P (SP) and its antagonist represent a radical new approach to the management of a number of diseases. SP is considered to have an impact on the smooth muscles. The SP receptor is highly expressed in areas of the brain that are implicated in these behaviors, but also in other areas such as the nucleus accumbens which mediate the motivational properties of both natural rewards and drugs [5].

The treatments accessible at present for chronic pain conditions are few and their use is limited by the severe side effects of these medications. For years, researchers have been trying to elucidate the molecular mechanisms that underlie central sensitization to develop novel approaches for treating chronic pain conditions. A variety of studies led to the hypothesis that SP and its NK1 receptor are involved in nociception [3,6]. However, highly specific antagonists of NK1 are failed to show significant analgesic potential in clinical trials [7], because it is not the NK1 receptor itself, but rather the spinal cord neurons that express NK1 which are pivotal for central sensitization and chronic pain [8]. Actually, they block behavioural responses to noxious and other stressful sensory stimuli at a level detectable in animals but fail to provide the level of sensory blockade required to produce clinical analgesia in humans [9]. According to researchers, NK1 receptor is crucial for central sensitization and chronic pain. Study of Mantyh and colleagues, which are based largely on the observations that SP is released upon peripheral noxious stimulation and activates spinal cord nociceptive-specific neurons [10], and that when SP binds to NK1, both SP and NK1 are internalized [11].

For molecular and cellular characterization, synaptic mechanisms underlying the sensitization of spinal cord NK1 expressing neurons are also studied. In that study, whole-cell patch clamp recordings were performed from dorsal horn NK1 expressing neurons in an acute spinal cord slice preparation [12]. Most spino-parabrachial neurons showed the gap-firing pattern while the bursting firing pattern was characteristic of spinop-PAG (periaqueductal grey) neurons [13]. Herbert and Holzer has thoroughly described hyperalgesic conditions in which NK1 receptor antagonists may be of therapeutic value and discusses possible reasons for the discrepancies between preclinical and clinical trials with NK1 receptor antagonists [14].

New drug designing and development is the current need because treatments currently available for chronic conditions are few and their use is limited by the severe side effects of these medications. The identification and development of novel effective treatments for chronic disorders with minimal side effects is still a challenge. In this regard, enormous progress has been done in synthetic chemistry and biotechnology but still safety profile of these drugs is a big question mark. Modulating SP receptor activity as a therapeutic strategy is the most attractive area of research to design and develop new molecules of meaningful clinical values for tomorrow.

References


